Moreover, designing prospective clinical SMARCA4-mutated or SMARCA4/KRAS-co-mutated NSCLC trials to evaluate targeted therapies and immunotherapy may lead to a better understanding of how to improve cancer patients’ outcomes and survival rates. Here, KRAS is linked to cancer.